MedTrace Logo

Selective Activation of the Adrenomedullin Receptors in Migraine

NCT07451769 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2026-03-09

No results posted yet for this study

Summary

Adrenomedullin is a neuropeptide implicated in the pathogenesis of migraine. This study investigates whether its administration, after pre-treatment with erenumab (a CGRP-receptor blocking monoclonal antibody), can trigger migraine attacks in individuals with migraine without aura.

Conditions

Interventions

DRUG

Adrenomedullin

Continous intravenous infusion of 20 mL (19.9 pmol/kg/min) adrenomedulin over 20 minutes

OTHER

Placebo

Continous intravenous infusion of 20 mL isotonic saline over 20 minutes

Sponsors & Collaborators

  • Danish Headache Center

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-10
Primary Completion
2027-03-10
Completion
2032-12-20

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07451769 on ClinicalTrials.gov